Pharmacometabonomics Technique to Identify Warfarin Response Using Nuclear Magnetic Resonance Spectroscopy

被引:3
作者
Bawadikji, Abdulkader A. [1 ]
Teh, Chin-Hoe [3 ]
Kader, Muhamad A. B. S. A. [2 ]
Sulaiman, Syed A. S. [1 ]
Ibrahim, Baharudin [1 ]
机构
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia
[2] Penang Hosp, Dept Cardiol, George Town, Malaysia
[3] Bruker Malaysia Sdn Bhd, Selangor, Malaysia
关键词
Warfarin; narrow therapeutic window; international normalized ratio; prothrombin time; pharmacometabonomics; nuclear magnetic resonance; NONVALVULAR ATRIAL-FIBRILLATION; DOSE REQUIREMENTS; GENE POLYMORPHISMS; DRUG-METABOLISM; THERAPY; ANTICOAGULATION; CYP2C9; METABOLOMICS; METAANALYSIS; STROKE;
D O I
10.2174/1389201018666171103141828
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Warfarin, an anticoagulant medication, is prescribed regularly despite of its bleeding tendency for the prevention and/or treatment of various thromboembolic conditions, such as deep vein thrombosis, and complications associated with atrial fibrillation, and myocardial infarction, but because of its narrow therapeutic window, it has a lot of interactions with drugs and diet. Methods: Warfarin relies on regular monitoring of International Normalized Ratio which is a standardized test to measure prothrombin time and appropriate dose adjustment. Pharmacometabonomics is a novel scientific field which deals with identification and quantification of the metabolites present in the metabolome using spectroscopic techniques such as Nuclear Magnetic Resonance (NMR). Pharmacometabonomics helps to indicate perturbation in the levels of metabolites in the cells and tissues due to drug or ingestion of any substance. NMR is one of the most widely-used spectroscopic techniques in metabolomics because of its reproducibility and speed. Results: There are many factors that influence the metabolism of warfarin, making changes in drug dosage common, and clinical factors like drug-drug interactions, dietary interactions and age explain for the most part the variability in warfarin dosing. Some studies have showed that pharmacogenetic testing for warfarin dosing does not improve health outcomes, and around 26% of the variation in warfarin dose requirements remains unexplained yet. Conclusion: Many recent pharmacometabonomics studies have been conducted to identify novel biomarkers of drug therapies such as paracetamol, aspirin and simvastatin. Thus, a technique such as NMR based pharmacometabonomics to find novel biomarkers in plasma and urine might be useful to predict warfarin outcome.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 65 条
  • [1] Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
    Altman R.
    Vidal H.O.
    [J]. Thrombosis Journal, 9 (1)
  • [2] [Anonymous], EUR HEART J
  • [3] Pharmacology and management of the vitamin K antagonists
    Ansell, Jack
    Hirsh, Jack
    Hylek, Elaine
    Jacobson, Alan
    Crowther, Mark
    Palareti, Gualtiero
    [J]. CHEST, 2008, 133 (06) : 160S - 198S
  • [4] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
    Aquilante, CL
    Langaee, TY
    Lopez, LM
    Yarandi, HN
    Tromberg, JS
    Mohuczy, D
    Gaston, KL
    Waddell, CD
    Chirico, MJ
    Johnson, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 291 - 302
  • [5] Au N, 2008, DRUG METAB REV, V40, P355, DOI [10.1080/03602530801952187, 10.1080/03602530801952187 ]
  • [6] Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine
    Backshall, Alexandra
    Sharma, Rohini
    Clarke, Stephen J.
    Keun, Hector C.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (09) : 3019 - 3028
  • [7] Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study
    Basanta, Maria
    Ibrahim, Baharudin
    Dockry, Rachel
    Douce, David
    Morris, Mike
    Singh, Dave
    Woodcock, Ashley
    Fowler, Stephen J.
    [J]. RESPIRATORY RESEARCH, 2012, 13
  • [8] Emergency Hospitalizations for Adverse Drug Events in Older Americans
    Budnitz, Daniel S.
    Lovegrove, Maribeth C.
    Shehab, Nadine
    Richards, Chesley L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (21) : 2002 - 2012
  • [9] Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism
    Clayton, T. Andrew
    Baker, David
    Lindon, John C.
    Everett, Jeremy R.
    Nicholson, Jeremy K.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (34) : 14728 - 14733
  • [10] Pharmaco-metabonomic phenotyping and personalized drug treatment
    Clayton, TA
    Lindon, JC
    Cloarec, O
    Antti, H
    Charuel, C
    Hanton, G
    Provost, JP
    Le Net, JL
    Baker, D
    Walley, RJ
    Everett, JR
    Nicholson, JK
    [J]. NATURE, 2006, 440 (7087) : 1073 - 1077